Triveni Engineering & Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 29, 2025, 7:47 am

Competitors of Triveni Engineering & Industries Ltd

All Competitor Stocks of Triveni Engineering & Industries Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:00 am

Below is a detailed analysis of the quarterly data for Triveni Engineering & Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,598.22 Cr.. The value appears to be declining and may need further review. It has decreased from 1,629.29 Cr. (Mar 2025) to 1,598.22 Cr., marking a decrease of 31.07 Cr..
• For Expenses, as of Jun 2025, the value is 1,544.82 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,321.17 Cr. (Mar 2025) to 1,544.82 Cr., marking an increase of 223.65 Cr..
• For Operating Profit, as of Jun 2025, the value is 53.40 Cr.. The value appears to be declining and may need further review. It has decreased from 308.12 Cr. (Mar 2025) to 53.40 Cr., marking a decrease of 254.72 Cr..
• For OPM %, as of Jun 2025, the value is 3.34%. The value appears to be declining and may need further review. It has decreased from 18.91% (Mar 2025) to 3.34%, marking a decrease of 15.57%.
• For Other Income, as of Jun 2025, the value is 22.98 Cr.. The value appears strong and on an upward trend. It has increased from 9.27 Cr. (Mar 2025) to 22.98 Cr., marking an increase of 13.71 Cr..
• For Interest, as of Jun 2025, the value is 38.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.11 Cr. (Mar 2025) to 38.15 Cr., marking an increase of 8.04 Cr..
• For Depreciation, as of Jun 2025, the value is 35.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.11 Cr. (Mar 2025) to 35.37 Cr., marking an increase of 3.26 Cr..
• For Profit before tax, as of Jun 2025, the value is 2.86 Cr.. The value appears to be declining and may need further review. It has decreased from 255.17 Cr. (Mar 2025) to 2.86 Cr., marking a decrease of 252.31 Cr..
• For Tax %, as of Jun 2025, the value is 26.57%. The value appears to be improving (decreasing) as expected. It has decreased from 26.67% (Mar 2025) to 26.57%, marking a decrease of 0.10%.
• For Net Profit, as of Jun 2025, the value is 2.10 Cr.. The value appears to be declining and may need further review. It has decreased from 187.12 Cr. (Mar 2025) to 2.10 Cr., marking a decrease of 185.02 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.20. The value appears to be declining and may need further review. It has decreased from 8.36 (Mar 2025) to 0.20, marking a decrease of 8.16.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:14 am

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: September 10, 2025, 2:42 pm

Below is a detailed analysis of the balance sheet data for Triveni Engineering & Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
• For Reserves, as of Mar 2025, the value is 3,089.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,879.00 Cr. (Mar 2024) to 3,089.00 Cr., marking an increase of 210.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1,980.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,424.00 Cr. (Mar 2024) to 1,980.00 Cr., marking an increase of 556.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,124.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 799.00 Cr. (Mar 2024) to 1,124.00 Cr., marking an increase of 325.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 6,215.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5,124.00 Cr. (Mar 2024) to 6,215.00 Cr., marking an increase of 1,091.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,334.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,517.00 Cr. (Mar 2024) to 2,334.00 Cr., marking an increase of 817.00 Cr..
• For CWIP, as of Mar 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 226.00 Cr. (Mar 2024) to 32.00 Cr., marking a decrease of 194.00 Cr..
• For Investments, as of Mar 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 55.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 45.00 Cr..
• For Other Assets, as of Mar 2025, the value is 3,840.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,326.00 Cr. (Mar 2024) to 3,840.00 Cr., marking an increase of 514.00 Cr..
• For Total Assets, as of Mar 2025, the value is 6,215.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,124.00 Cr. (Mar 2024) to 6,215.00 Cr., marking an increase of 1,091.00 Cr..

Notably, the Reserves (3,089.00 Cr.) exceed the Borrowings (1,980.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Triveni Engineering & Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 10.88. This value is within the healthy range. It has decreased from 18.05 (Mar 24) to 10.88, marking a decrease of 7.17.
• For Diluted EPS (Rs.), as of Mar 25, the value is 10.88. This value is within the healthy range. It has decreased from 18.05 (Mar 24) to 10.88, marking a decrease of 7.17.
• For Cash EPS (Rs.), as of Mar 25, the value is 16.65. This value is within the healthy range. It has decreased from 22.81 (Mar 24) to 16.65, marking a decrease of 6.16.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 142.13. It has increased from 132.52 (Mar 24) to 142.13, marking an increase of 9.61.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 142.13. It has increased from 132.52 (Mar 24) to 142.13, marking an increase of 9.61.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 259.90. It has increased from 238.47 (Mar 24) to 259.90, marking an increase of 21.43.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 24.38. This value is within the healthy range. It has decreased from 31.45 (Mar 24) to 24.38, marking a decrease of 7.07.
• For PBIT / Share (Rs.), as of Mar 25, the value is 18.62. This value is within the healthy range. It has decreased from 26.69 (Mar 24) to 18.62, marking a decrease of 8.07.
• For PBT / Share (Rs.), as of Mar 25, the value is 14.81. This value is within the healthy range. It has decreased from 24.17 (Mar 24) to 14.81, marking a decrease of 9.36.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 10.88. This value is within the healthy range. It has decreased from 18.05 (Mar 24) to 10.88, marking a decrease of 7.17.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.11. This value is within the healthy range. It has decreased from 18.05 (Mar 24) to 11.11, marking a decrease of 6.94.
• For PBDIT Margin (%), as of Mar 25, the value is 9.38. This value is below the healthy minimum of 10. It has decreased from 13.18 (Mar 24) to 9.38, marking a decrease of 3.80.
• For PBIT Margin (%), as of Mar 25, the value is 7.16. This value is below the healthy minimum of 10. It has decreased from 11.19 (Mar 24) to 7.16, marking a decrease of 4.03.
• For PBT Margin (%), as of Mar 25, the value is 5.69. This value is below the healthy minimum of 10. It has decreased from 10.13 (Mar 24) to 5.69, marking a decrease of 4.44.
• For Net Profit Margin (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 5. It has decreased from 7.56 (Mar 24) to 4.18, marking a decrease of 3.38.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 8. It has decreased from 7.56 (Mar 24) to 4.27, marking a decrease of 3.29.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.81. This value is below the healthy minimum of 15. It has decreased from 13.62 (Mar 24) to 7.81, marking a decrease of 5.81.
• For Return on Capital Employeed (%), as of Mar 25, the value is 10.84. This value is within the healthy range. It has decreased from 17.57 (Mar 24) to 10.84, marking a decrease of 6.73.
• For Return On Assets (%), as of Mar 25, the value is 3.89. This value is below the healthy minimum of 5. It has decreased from 7.72 (Mar 24) to 3.89, marking a decrease of 3.83.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 0.2. It has increased from 0.08 (Mar 24) to 0.12, marking an increase of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.63. This value is within the healthy range. It has increased from 0.48 (Mar 24) to 0.63, marking an increase of 0.15.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.00. It has decreased from 1.09 (Mar 24) to 1.00, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has decreased from 1.72 (Mar 24) to 1.46, marking a decrease of 0.26.
• For Quick Ratio (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has decreased from 0.37 (Mar 24) to 0.35, marking a decrease of 0.02.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 4. It has increased from 1.80 (Mar 24) to 2.21, marking an increase of 0.41.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.25. This value is below the healthy minimum of 20. It has decreased from 42.93 (Mar 24) to 11.25, marking a decrease of 31.68.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 7.41. This value is below the healthy minimum of 20. It has decreased from 33.97 (Mar 24) to 7.41, marking a decrease of 26.56.
• For Earning Retention Ratio (%), as of Mar 25, the value is 88.75. This value exceeds the healthy maximum of 70. It has increased from 57.07 (Mar 24) to 88.75, marking an increase of 31.68.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 92.59. This value exceeds the healthy maximum of 70. It has increased from 66.03 (Mar 24) to 92.59, marking an increase of 26.56.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.40. This value is within the healthy range. It has decreased from 12.40 (Mar 24) to 6.40, marking a decrease of 6.00.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.85. This value is within the healthy range. It has decreased from 8.12 (Mar 24) to 3.85, marking a decrease of 4.27.
• For Enterprise Value (Cr.), as of Mar 25, the value is 10,373.98. It has increased from 8,132.15 (Mar 24) to 10,373.98, marking an increase of 2,241.83.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.82. This value is within the healthy range. It has increased from 1.56 (Mar 24) to 1.82, marking an increase of 0.26.
• For EV / EBITDA (X), as of Mar 25, the value is 19.44. This value exceeds the healthy maximum of 15. It has increased from 11.81 (Mar 24) to 19.44, marking an increase of 7.63.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.48, marking an increase of 0.18.
• For Retention Ratios (%), as of Mar 25, the value is 88.74. This value exceeds the healthy maximum of 70. It has increased from 57.06 (Mar 24) to 88.74, marking an increase of 31.68.
• For Price / BV (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has increased from 2.34 (Mar 24) to 2.70, marking an increase of 0.36.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.48, marking an increase of 0.18.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness